Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod Effectiveness and Safety in Chinese Participants with Relapsing Multiple Sclerosis
NCT06396039Phase 4Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ozanimod in multiple sclerosis (MS), sponsored by Bristol Myers Squibb. Started May 2024; status: active, not recruiting.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06396039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06396039.